Beremagene Geperpavec

Summary

Beremagene Geperpavec (CHEMBL4594328) is an approved gene (ATC D03AX16); indicated across 5 conditions including epidermolysis bullosa dystrophica and injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• ATC class: D03AX16
• Indications: 5 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594328
Name	Beremagene Geperpavec
Type	Gene
Max phase	4
ATC	D03AX16

Also known as: Beremagene geperpavec, Beremagene geperpavec-svdt, KB-103, KB103, Vyjuvek, BEREMAGENE GEPERPAVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epidermolysis bullosa dystrophica	4	MONDO:0006543	MONDO:0009179
injury	4	MONDO:0021178	EFO:0000546

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04491604	PHASE3	COMPLETED	Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
NCT03536143	PHASE1/PHASE2	COMPLETED	A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).